# US 11,077,134 B1 · Water dissolvable macrocyclic lactone cyclodextrin complexes > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,077,134 B1 - Document ID: US11077134B1 - Status: Granted - Kind: B1 - Application number: 17/132,203 - Filed: 2020-12-23 - Granted: 2021-08-03 - Earliest claimed: 2020-11-10 - Assignees: Mountain Valley Md Inc. - Applicants: Mountain Valley Md Inc - Inventors: Michael Farber - Web page: https://patentgrep.com/patent/US11077134B1 ## CPC - A61K 31/724: Cyclodextrins - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)} - A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant - A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin - A61K 47/40: Cyclodextrins; Derivatives thereof - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 50 micrograms to 500 milligrams of the macrocyclic lactone complex per 5 milliliters of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex. ## Claims ### Claim 1 A non-toxic macrocyclic lactone solution, without an organic solvent, comprising: a macrocyclic lactone with a cyclodextrin complex formed into a macrocyclic lactone cyclodextrin complex; a surfactant; wherein said macrocyclic lactone is an ivermectin or an ivermectin derivative; and wherein said macrocyclic lactone cyclodextrin complex is completely dissolvable or dissolved in water in a ratio of at least 20 mg of macrocyclic lactone to 1 mL of water. ### Claim 2 (depends on 1) The solution of claim 1, wherein said cyclodextrin of said macrocyclic lactone cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin. ### Claim 3 (depends on 1) The solution of claim 1, wherein said surfactant is polysorbate 80 and is 0.01% to 25%, by weight, of said water. ### Claim 4 (depends on 2) The solution of claim 2, wherein said solution is safely injectable at a dosage of approximately 20 to 400 micrograms per kilogram in an animal selected from the group consisting of swine, cattle, poultry, human, and husbanded animal. ### Claim 5 (depends on 2) The solution of claim 2, formed, in at least in part, by: placing said macrocyclic lactone cyclodextrin complex, in a solution or a powdered form, into a vial; adding water to the vial comprising macrocyclic lactone cyclodextrin complex; adding surfactant to the vial comprising macrocyclic lactone cyclodextrin complex; and agitating said vial while or after adding said surfactant until said macrocyclic lactone cyclodextrin complex is fully dissolved in water. ### Claim 6 (depends on 1) The solution of claim 1, wherein said macrocyclic lactone solution is encased in a liposome. ### Claim 7 (depends on 1) The solution of claim 1, wherein said macrocyclic lactone solution is capable of being administered by inhalation. ### Claim 8 (depends on 1) The composition of claim 1, the macrocyclic lactone cyclodextrin complex with the surfactant is completely dissolvable or dissolved in water in a ratio of at least 40 mg of macrocyclic lactone to 1 mL of water. ### Claim 9 A method of forming a non-toxic macrocyclic lactone solution without the use of organic solvents, comprising: forming or providing a macrocyclic lactone with a cyclodextrin complex into a macrocyclic lactone cyclodextrin complex wherein said macrocyclic lactone is an ivermectin or an ivermectin derivative: adding a surfactant to said macrocyclic lactone complex; adding water to the macrocyclic lactone cyclodextrin complex; wherein the macrocyclic lactone cyclodextrin complex with the surfactant is completely dissolvable or dissolved in water in a ratio of at least 20 mg of macrocyclic lactone to 1 mL of water. ### Claim 10 (depends on 1) The method of claim 1, wherein said cyclodextrin of said macrocyclic lactone cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin. ### Claim 11 (depends on 10) The method of claim 10, wherein said surfactant is polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. ### Claim 12 (depends on 9) The method of claim 9, wherein said solution is safely injectable at a dosage of approximately 20 to 400 micrograms per kilogram in an animal selected from the group consisting of swine, cattle, poultry, human, and husbanded animal. ### Claim 13 (depends on 9) The method of claim 9, further comprising placing said macrocyclic lactone cyclodextrin complex, in a solution or a powdered form, into a vial; adding water to the vial comprising macrocyclic lactone cyclodextrin complex; adding surfactant to the vial comprising macrocyclic lactone cyclodextrin complex; and agitating said vial while or after adding said surfactant until said macrocyclic lactone cyclodextrin complex is fully dissolved in water. ### Claim 14 (depends on 9) The method of claim 9, wherein the macrocyclic lactone cyclodextrin complex with the surfactant is completely dissolvable or dissolved in water in a ratio of at least 40 mg of macrocyclic lactone to 1 mL of water.